Q-omics provides the consensus-scored RAET1L profile across patient tissues and cancer cell-line models. RAET1L expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAET1L is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, RAET1L RNA expression shows 13,157 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where RAET1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAET1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAET1L survival associations across molecular data types. RAET1L RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAET1L RNA expression–survival associations across cancer types. High RAET1L expression shows unfavorable associations in KIRC, BRCA, LUAD, SKCM, BLCA and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for RAET1L RNA expression.
This table summarizes RAET1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RAET1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAET1L shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, LUSC, LUAD and THCA. The KIRC box plot shows higher RAET1L RNA expression in normal versus tumor tissue (log2 FC = −0.696, t-test p < 0.001).
This table shows molecular features associated with RAET1L in patient tissues and cancer cell lines. In patient samples, RAET1L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RAET1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
